RecruitingTricuspid Valve Regurgitation
Clinical Study of the inQB8 TTVR System (The MonarQ Study)
Eligible age
18+ yrs
Accepts
All genders
Locations
5 states
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
Prospective, multi-center study to assess safety and performance of the inQB8 MonarQ Tricuspid Valve Replacement System.
Sponsor: inQB8 Medical Technologies, LLC
You may qualify if…
- ✓ Anatomically suitable for the MonarQ TTVR System
- ✓ Symptomatic, tricuspid regurgitation (TR) that is severe or greater
- ✓ Adequately treated for heart failure based upon medical standards
- ✓ Hemodynamically stable
You may not qualify if…
- ✕ Need for emergent or urgent surgery for any reason, any planned cardiac surgery within the next 12 months (365 days), or any planned percutaneous cardiac procedure within the next 90 days
- ✕ Refractory Heart Failure (HF) that requires or required advanced intervention
- ✕ Any condition, in the opinion of the investigator, making it unlikely the patient will be able to complete all protocol procedures and follow-up.
- ✕ Currently participating in another investigational biologic, drug or device study
Where it's recruiting
California
Los Angeles · Thousand Oaks
Georgia
Atlanta
New York
Manhasset
Pennsylvania
Philadelphia
Texas
Plano
Source: ClinicalTrials.gov · NCT06611579 · last updated 2026-05-18